Characteristic | Cohort 1 | Cohort 2 |
---|---|---|
Vemurafenib 6 weeks (N = 38) | Vemurafenib 7–18 weeks (N = 15) | |
Age (yr) | ||
 Mean (SD) | 48.6 (12.79) | 48.5 (13.90) |
 Median | 50.5 | 48.0 |
 Range | 21–73 | 26–67 |
Gender – no. (%) | ||
 Male | 15 (39.5) | 6 (40.0) |
 Female | 23 (60.5) | 9 (60.0) |
Race – no. (%) | ||
 White | 35 (92.1) | 15 (100.0) |
 Decline | 2 (5.3) | 0 (0.0) |
 Other | 1 (2.6) | 0 (0.0) |
Metastasis stage – no. (%) | ||
 M1a | 9 (23.7) | 2 (13.3) |
 M1b | 13 (34.2) | 3 (20.0) |
 M1c | 16 (42.1) | 10 (66.7) |
LDH level – no. (%) | ||
  ≤ ULN | 17 (44.7) | 5 (33.3) |
  > ULN | 17 (44.7) | 8 (53.3) |
 Not measured | 4 (10.5) | 2 (13.3) |
Prior therapy – no. (%) | ||
 Surgery | 34 (89.5) | 13 (86.7) |
 Radiation | 7 (18.4) | 8 (53.3) |
 Chemotherapy | 4 (10.5) | 1 (6.7) |
 Anti-PD1/PDL1 | 0 | 0 |
Mutation – no. (%) | ||
 BRAF | 38 (100.0) | 15 (100.0) |
 cKIT | 1 (2.6) | 0 (0.0) |
 Other | 1 (2.6) | 0 (0.0) |
Performance Status | ||
 0 | 24 (63.2) | 8 (53.3) |
 1 | 14 (36.8) | 7 (46.7) |